FOXO4-DRI
Research profile · How we handle evidence
FOXO4-DRI is a senolytic-style research peptide designed to interfere with the FOXO4–p53 interaction that shows up in some senescent (aging) cell states. In preclinical work it’s been used as a probe for how blocking this axis can shift the balance toward removal of senescent cells.
Evidence Score
Preclinical signal
Category
Therapeutic area
Standard Dose
Daily
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Limited data
Overview
Think of FOXO4-DRI as a research tool aimed at a specific protein interaction linked with cellular senescence. Most of the evidence is preclinical, so any real-world expectations should stay conservative and uncertainty-forward.
Mechanism of Action
Think of FOXO4-DRI as a research tool aimed at a specific protein interaction linked with cellular senescence. Most of the evidence is preclinical, so any real-world expectations should stay conservative and uncertainty-forward.
pH & Mixing
Peptides reconstituted at very different pH levels can destabilize when combined in the same syringe, which lowers how much of the peptide your body actually absorbs. If you're unsure whether two peptides are close enough in pH, reconstitute and inject them separately.
A dedicated compatibility check between two specific peptides is coming to the Compare tool. This section covers this peptide's pH only.
Benefits
- Senolytic (eliminates senescent cells)
- Tissue rejuvenation
- Anti-aging
- Reduces age-related inflammation
Side Effects
- Limited human data
- Possible inflammatory response
Contraindications
- Pregnant or breastfeeding women
- Active cancer
Structure & Sequence
Verified structure
FOXO4-DRI
Sequence illustration backed by PubChem match.
- Amino Acid Sequence
- LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRP (D-amino acid retro-inverso)
- Molecular Weight
- ~5,358 Da
- Chemical Formula
- C228H388N86O64
- CAS Number
- N/A
- Reconstituted pH
- 10.9
- InChIKey
- WVZCDZFJLXBWHG-XXZPGMBKSA-N
Stack & Route Context
Stacks with
- Epitalon
- MOTS-c
Administration
Subcutaneous
Research Status
Preclinical research for anti-aging
Approval Status
Preclinical
Sports Legal
Permitted
References
- 1View source
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
2025
- 2View source
Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis
2016
- 3View source
Regulation of cellular senescence via the FOXO4–p53 axis
2018
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.